Clinical trial · Interventional
Is Involucrin Has a Role in Verruca Vulgaris? A Clinical and Immunohistochemical Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Vitamin D3 plays important role in keratinocyte differentiation and had been used recently in verruca vulgaris. Aim of the work: To assess the expression of involucrin in verrucae vulgaris before and after injection of vitamin D3. Subjects and Methods: This study included 60 patients with verrucae vulgaris subjected to intralesional injection of vitamin D3 at three weeks interval for a maximum of five sessions. Immunohistochemical assessment of involucrin was done before and after injection and compared to skin biopsies from 30 healthy individuals
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Involucrin | — | UNRESOLVED | — |
| Verruca Vulgaris | Verruca Vulgaris | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cholecalciferol | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Cholecalciferol injection
- interventionNames
- Drug: Cholecalciferol
Primary outcomes (1)
- measure
- Resolution of verrucae
- timeFrame
- 3 months
- description
- Decrease of verrucae size Decrease of verrucae number
Secondary outcomes (1)
- measure
- Involucrin expression
- timeFrame
- 3 months
- description
- Change of expression pattern of involucrin by immunohistochemical study Change of expression grade of involucrin by immunohistochemical study
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion criteria: Patients with multiple verruca vulgaris Patients with with verrucae vulgaris with size more than 3 cm Exclusion Criteria: Patients with a past history of allergic response to vitamin D. Pregnant or lactating females. Hepatic patients. Renal patients. Patients with bleeding tendency.
References
Publications (0)
Data not yet available